Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC) (A221602)

Olanzapine with or without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC) (A221602)

Trial Category:
Symptom Management
Phase
III
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Faith Regional Health System, Carson Cancer Center, Norfolk, NE
Great Plains Health, Callahan Cancer Center, North Platte, NE
Nebraska Cancer Specialists, Omaha, NE
Nebraska Hematology Oncology, Lincoln, NE
Regional West Health Services, Cancer Center, Scottsbluff, NE
Southeast Nebraska Cancer Center, Lincoln, NE

This study is looking at whether the drug Fosaprepitant is needed prior to chemotherapy drugs that are known to cause nausea and vomiting ( highly emetogenic chemotherapy), or whether a more cost effective method of oral Olanzapine tablets  combined with steroid tablets could be subsituted.  Oral Olanzapine is provided free of charge to patients who participate.

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members